Search Results

There are 10002 results for: content related to: A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

  1. You have free access to this content
    Bortezomib for the treatment of multiple myeloma

    Intervention Review

    The Cochrane Library

    Kathleen Scott, Patrick J Hayden, Andrea Will, Keith Wheatley and Imelda Coyne

    Published Online : 20 APR 2016, DOI: 10.1002/14651858.CD010816.pub2

  2. You have free access to this content
    The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

    British Journal of Haematology

    Volume 161, Issue 1, April 2013, Pages: 43–56, Girija Dasmahapatra, Hiral Patel, Paul Dent, Richard I. Fisher, Jonathan Friedberg and Steven Grant

    Version of Record online : 30 JAN 2013, DOI: 10.1111/bjh.12206

  3. You have free access to this content
    Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma

    British Journal of Haematology

    Volume 168, Issue 1, January 2015, Pages: 55–62, Michelle Furtado, Rod Johnson, Anton Kruger, Deborah Turner and Simon Rule

    Version of Record online : 22 AUG 2014, DOI: 10.1111/bjh.13101

  4. You have free access to this content
    Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines

    British Journal of Haematology

    Volume 167, Issue 5, December 2014, Pages: 639–650, Kwai Fung Hui, Yvonne Y. Leung, Po L. Yeung, Jaap M. Middeldorp and Alan K.S. Chiang

    Version of Record online : 25 AUG 2014, DOI: 10.1111/bjh.13089

  5. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

    British Journal of Haematology

    Jacob P. Laubach, Javid J. Moslehi, Sanjeev A. Francis, Jesús F. San Miguel, Pieter Sonneveld, Robert Z. Orlowski, Philippe Moreau, Laura Rosiñol, Edward A. Faber Jr, Peter Voorhees, Maria-Victoria Mateos, Loreta Marquez, Huaibao Feng, Avinash Desai, Helgi van de Velde, Jennifer Elliott, Hongliang Shi, Edward Dow, Nishith Jobanputra, Dixie-Lee Esseltine, Liviu Niculescu, Kenneth C. Anderson, Sagar Lonial and Paul G. Richardson

    Version of Record online : 3 MAY 2017, DOI: 10.1111/bjh.14708

  6. Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells

    Journal of Periodontal Research

    Volume 50, Issue 2, April 2015, Pages: 248–255, J. Kitagaki, S. Miyauchi, C. J Xie, M. Yamashita, S. Yamada, M. Kitamura and S. Murakami

    Version of Record online : 20 JUN 2014, DOI: 10.1111/jre.12202

  7. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study

    British Journal of Haematology

    Orhan Sezer, Meral Beksac, Roman Hajek, Gülsan Sucak, Seckin Cagirgan, Werner Linkesch, Olga Meltem Akay, Zafer Gülbas, Hareth Nahi, Torben Plesner, John A. Snowden, Ayşen Timurağaoğlu, Tobias Dechow, Alois Lang, Tülin Tuğlular, Johannes Drach, Gabriele Armbrecht, Anna Potamianou, Catherine Couturier, Robert A. Olie, Caroline Feys, Nathalie Allietta and Evangelos Terpos

    Version of Record online : 6 APR 2017, DOI: 10.1111/bjh.14637

  8. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

    Molecular Carcinogenesis

    Volume 52, Issue 2, February 2013, Pages: 118–133, Daniel R. Premkumar, Esther P. Jane, Naomi R. Agostino, Joseph D. DiDomenico and Ian F. Pollack

    Version of Record online : 15 NOV 2011, DOI: 10.1002/mc.21835

  9. You have free access to this content
    NFKB1 −94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma

    British Journal of Haematology

    Volume 168, Issue 5, March 2015, Pages: 679–688, Gergely Varga, Gábor Mikala, Hajnalka Andrikovics, Magdalena Koszarska, Katalin Balassa, Emma Ádám, András Kozma, Attila Tordai and Tamás Masszi

    Version of Record online : 3 NOV 2014, DOI: 10.1111/bjh.13197

  10. You have free access to this content
    Proteasome inhibition aggravates tumor necrosis factor–mediated bone resorption in a mouse model of inflammatory arthritis

    Arthritis & Rheumatism

    Volume 63, Issue 3, March 2011, Pages: 670–680, Karin Polzer, Kirsten Neubert, Silke Meister, Benjamin Frey, Wolfgang Baum, Jörg H. Distler, Eva Gückel, Georg Schett, Reinhard E. Voll and Jochen Zwerina

    Version of Record online : 25 FEB 2011, DOI: 10.1002/art.30177

  11. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines

    International Journal of Laboratory Hematology

    Volume 34, Issue 3, June 2012, Pages: 237–247, B. ZHENG, R. ZHOU, Y. GONG, X. YANG and Q. SHAN

    Version of Record online : 7 DEC 2011, DOI: 10.1111/j.1751-553X.2011.01384.x

  12. You have full text access to this Open Access content
    Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition

    Cancer Science

    Volume 101, Issue 6, June 2010, Pages: 1403–1408, Daisuke Tamura, Tokuzo Arao, Kaoru Tanaka, Hiroyasu Kaneda, Kazuko Matsumoto, Kanae Kudo, Keiichi Aomatsu, Yoshihiko Fujita, Takashi Watanabe, Nagahiro Saijo, Yoshikazu Kotani, Yoshihiro Nishimura and Kazuto Nishio

    Version of Record online : 15 MAR 2010, DOI: 10.1111/j.1349-7006.2010.01544.x

  13. You have free access to this content
    Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells

    International Journal of Cancer

    Volume 133, Issue 6, 15 September 2013, Pages: 1357–1367, I.S. Song, H.K. Kim, S.R. Lee, S.H. Jeong, N. Kim, K.S. Ko, B.D. Rhee and J. Han

    Version of Record online : 4 APR 2013, DOI: 10.1002/ijc.28149

  14. You have free access to this content
    A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

    British Journal of Haematology

    Volume 169, Issue 1, April 2015, Pages: 36–43, Saulius K. Girnius, Saem Lee, Suman Kambhampati, Michal G. Rose, Abid Mohiuddin, Antoun Houranieh, Abraham Zimelman, Terrence Grady, Paulette Mehta, Caroline Behler, Teresa G. Hayes, Yvonne A. Efebera, Rao H. Prabhala, Andrew Han, Sarvari V. Yellapragada, Catherine E. Klein, Garson D. Roodman, Alan Lichtenstein and Nikhil C. Munshi

    Version of Record online : 8 JAN 2015, DOI: 10.1111/bjh.13243

  15. Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy

    Glia

    Volume 58, Issue 16, December 2010, Pages: 1961–1976, Yoon Kyung Shin, So Young Jang, Hyun Kyoung Lee, Junyang Jung, Duk Joon Suh, Su-Yeong Seo and Hwan Tae Park

    Version of Record online : 9 SEP 2010, DOI: 10.1002/glia.21065

  16. You have full text access to this Open Access content
    Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies

    Molecular Oncology

    Volume 9, Issue 1, January 2015, Pages: 309–322, Ahmed E. Goda, Raymond L. Erikson, Toshiyuki Sakai, Jong-Seog Ahn, Bo-Yeon Kim

    Version of Record online : 6 SEP 2014, DOI: 10.1016/j.molonc.2014.08.010

  17. You have free access to this content
    The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer

    International Journal of Cancer

    Volume 137, Issue 3, 1 August 2015, Pages: 686–697, Sonja Thaler, Gitta Thiede, Jan G. Hengstler, Arno Schad, Marcus Schmidt and Jonathan P. Sleeman

    Version of Record online : 8 JAN 2015, DOI: 10.1002/ijc.29404

  18. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer

    Journal of Surgical Oncology

    Volume 105, Issue 4, 15 March 2012, Pages: 357–364, Annette Wunderlich, Tjadina Arndt, Melina Fischer, Silvia Roth, Annette Ramaswamy, Brandon H. Greene, Cornelia Brendel, Ulrike Hinterseher, Detlef K. Bartsch and Sebastian Hoffmann

    Version of Record online : 17 OCT 2011, DOI: 10.1002/jso.22113

  19. You have free access to this content
    Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: 314–319, María Victoria Mateos, Paul G. Richardson, Meletios A. Dimopoulos, Antonio Palumbo, Kenneth C. Anderson, Hongliang Shi, Jennifer Elliott, Edward Dow, Helgi van de Velde, Liviu Niculescu and Jesús F. San Miguel

    Version of Record online : 27 FEB 2015, DOI: 10.1002/ajh.23933

  20. You have free access to this content
    Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically

    BJU International

    Volume 109, Issue 8, April 2012, Pages: 1258–1268, Akinori Sato, Takako Asano, Keiichi Ito, Makoto Sumitomo and Tomohiko Asano

    Version of Record online : 2 SEP 2011, DOI: 10.1111/j.1464-410X.2011.10533.x